Cardiac ion channels and antihistamines: Possible mechanisms of cardiotoxicity

Clinical and Experimental Allergy, Supplement

Volumn 29, Issue 3, 1999, Pages 182-189

  Taglialatela, M ^a   Castaldo, P ^a   Pannaccione, A ^a   Giorgio, G ^a   Genovese, A ^a   Marone, G ^a   Annunziato, L ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Antihistimes; Drug induced toxicity; Ether a gogo related gene (HERG); K+ channels; Long QT syndrome

Indexed keywords

ACRIVASTINE; ANTIHISTAMINIC AGENT; ASTEMIZOLE; CETIRIZINE; EBASTINE; FEXOFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; ION CHANNEL; LORATADINE; POTASSIUM CHANNEL; TERFENADINE;

CARDIOTOXICITY; DRUG MECHANISM; HEART ARRHYTHMIA; HEART MUSCLE POTENTIAL; HUMAN; LONG QT SYNDROME; PRIORITY JOURNAL; REVIEW; TORSADE DES POINTES;

EID: 0032783924     PISSN: 09602178     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.1999.0290s3182.x     Document Type: Review

References (38)

1. Babe KS, Serafin WE. Histamine, bradykinin, and their antagonists. In: Hardman JG, Goodman Gilman A, Limbird LE, eds. Goodmans and Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 1996:581-600.
2. Loew ER. Pharmacology of antihistamine compounds. Physiol Rev 1947; 27:542-73.
3. Johnson EA. The effect of anitfibrillatory drugs on the cat's heart in vivo. Br J Pharmacol Chemother 1954; 9:341-5.
4. Giotti A, Zilletti L. Antiarrhythmic actions of antihistamines. In: Szekeres L ed. Pharmacology of Antiarrhythmic Agents. Oxford: Pergamon Press 1981: 195-239.
5. Hollister LE. Hydroxyzine hydrochloride: possible adverse cardiac interactions. Psychopharmacol Commun 1975; 1:61-65.
6. Sorkin EM, Heel RC. Terfenadine: a review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1985; 29:34-56.
7. Woosley RL. Cardiac actions of antihistamines. Annu Rev Pharmacol Toxicol 1996; 36:233-52.
8. Jackman WM, Friday KJ, Anderson JL, Aliot EM, Clark M, Lazzara R. The long QT syndrome: a critical review, new clinical oservations and a unifying hypothesis. Prog Cardiovasc Dis 1988; 31:115-72.
9. Dessertenne F. La tachycardie ventriculaire a deux foyers opposes variables. Arch Mal Coeur 1966; 95:263-72.
10. Craft TM. Torsade de pointes after astemizole overdose. Br Med J 1986; 292:660.
11. Davies AJ, Harinda V, McHewan A, Ghose RR. Cardiotoxic effect with convulsions in terfenadine overdose. Br Med J 1989; 302:1469.
12. Monahan BP, Ferguson CL, Killeavy ES, et al. Torsade de pointes occurring in association with terfenadine use. J Am Med Assoc 1990; 264:2788-90.
13. 1-Receptor Antagonists in Allergic Diseases. New York: Marcel Dekker Inc. 1996:383-412.
14. Hey JA, del Prado M, Sherwood J, Kreutner W, Egan RW. Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects. Arznemittel-Forschung Drug Res 1996; 46:153-6.
15. Roberts DJ, Llenas J. Second generation antihistamines. Some observations on the cardiotoxic and drug interaction profiles of second generation antihistamines as measured in the guinea-pig. Arz-Forsch Drug Res 1996; 46:832-3.
16. Lindquist M, Edwards IR. Risk of non-sedating antihistamines. Lancet 1997; 349:1322.
17. Carmeliet E. Mechanisms and control of repolarization. Eur Heart J 1993; 14:3-13.
18. + current: differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 1990; 96:195-215.
19. Schwartz PJ, Locati EH, Napolitano C, Priori SG. The long QT syndrome. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology From Cell to Bedside. Philadelphia: W.B. Saunders Co. 1995:788-811.
20. Warmke JW, Ganetzky B. A family of potassium channel genes related to eag in Drosofila and mammals. Proc Natl Acad Sci USA 1994; 91:3438-42.
21. Curran ME, Splawski I, Timothy KW, et al. A molecular basis for cardiac arrhythmia: HERG mutations cause the long QT syndrome. Cell 1995; 80:795-803.
22. Kr potassium channel. Cell 1995; 81:299-307.
23. Smith PL, Baukrowitz T, Yellen G. The inward rectification mechanism of the HERG cardiac potassium channel. Nature 1996; 379:833-6.
24. Kr. Nature 1997; 388:289-92.
25. Berul CI, Morad M. Regulation of potassium channels by nonsedating antihistamines. Circulation 1995; 91:2220-5.
26. 1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ Res 1995; 76:110-19.
27. Roy M-L, Dumaine R, Brown AM. HERG, a primary human ventricular target of the non sedating antihistamine terfenadine. Circulation 1996; 94:817-23.
28. Suessbrich H, Waldegger S, Lang F, Busch AE. Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett 1996; 385:77-80.
29. + channel family by Ebastine. J Pharmacol Exp Ther 1997; 281:233-44.
30. Haria M, Fitton A, Peters DH. Loratadine. A reappraisal of its pharmacodynamic properties and therapeutic use in allergic disorders. Drugs 1994; 48:617-38.
31. 1 receptor blocker cetirizine as compared to other second-generation antihistamines. Mol Pharmacol 1998; 54:113-21.
32. Lacerda AE, Roy M-L, Lewis EW, Rampe D. Interaction of the nonsedating antihistamine loratadine with a Kv1.5 type potassium channel cloned from human heart. Mol Pharmacol 1997; 52:314-22.
33. Vorperian VR, Zhou Z, Mohammad S, et al. Torsade de pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole. J Am Coll Cardiol 1996; 28:1556-61.
34. Yang T, Prakash C, Roden DM, Snyders DJ. Mechanism of block of a human cardiac potassium channel by terfenadine racemate and enantiomers. Br J Pharmacol 1995; 115:267-74.
35. 2+ channel current in rat ventricular myocytes by terfenadine. Circ Res 1997; 81:202-10.
36. Zhang M-Q. Chemistry underlying the cardiotoxicity of antihistamines. Curr Med Chem 1997; 4:187-200.
37. 1 receptor activation reduces a background leakage potassium current. Neuroscience 1994; 59:579-88.
38. Shi W, Wymore RS, Wang H-S, et al. Identification of two nervous system-specific members of the erg potassium channel gene family. J Neurosci 1997; 17:9423-32.